The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine

被引：0
|
作者：
Papageorgiou, Sotirios
Kontos, Christos K.
Tsiambalis, Thomas
Vyniou, Athina
Symeonidis, Argiris
Galanopoulos, Athanasios
Kotsianidis, Ioannis
Pappa, Vassiliki
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4252
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine
    Hwang, Kyung-Lim
    Song, Moo-Kon
    Shin, Jin
    Na, Hae-Jung
    Shin, Dong-Hun
    Kim, Joong-Keun
    Moon, Joon-Ho
    Ahn, Jae-Sook
    Song, Ik-Chan
    Hong, Junshik
    Lee, Gyeong-won
    Chung, Joo-Seop
    BLOOD RESEARCH, 2014, 49 (04) : 234 - 240
  • [22] Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes
    Gangat, Naseema
    Patnaik, Mrinal M.
    Begna, Kebede
    Kourelis, Taxiarchis
    Knudson, Ryan A.
    Ketterling, Rhett P.
    Hodnefield, Janice M.
    Hanson, Curtis A.
    Pardanani, Animesh
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (08) : 690 - 693
  • [23] ANALYSIS OF POSSIBLE BIOMARKERS TO PREDICT RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE
    Kuendgen, A.
    Mueller-Thomas, C.
    Lauseker, M.
    Urbaniak, P.
    Haferlach, T.
    Alpermann, T.
    Meggendorfer, M.
    Schnittger, S.
    Brings, C.
    Wulfert, M.
    Hildebrandt, B.
    Betz, B.
    Royer-Pokora, B.
    Haas, R.
    Gattermann, N.
    Germing, U.
    Goetze, K.
    LEUKEMIA RESEARCH, 2015, 39 : S82 - S82
  • [24] Prognostic Role of Adaptive Immune Microenvironment in Patients with High-Risk Myelodysplastic Syndromes Treated with 5-Azacytidine
    Tsakiraki, Zoi
    Spathis, Aris
    Bouchla, Anthi
    Pouliakis, Abraham
    Vryttia, Pinelopi
    Panayiotides, Ioannis G.
    Pappa, Vasiliki
    Papageorgiou, Sotiris G.
    Foukas, Periklis G.
    CANCERS, 2025, 17 (07)
  • [25] Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response
    Breccia, Massimo
    Loglisci, Giuseppina
    Cannella, Laura
    Finsinger, Paola
    Mancini, Marco
    Serrao, Alessandra
    Santopietro, Michelina
    Salaroli, Adriano
    Alimena, Giuliana
    LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 985 - 986
  • [26] The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).
    Kenealy, Melita K.
    Seymour, John F.
    Linda, Cowan
    Milner, Alvin
    Giri, Pratyush
    Ho, Shir-Jing
    Benson, Warwick
    Nicol, Andrew
    Campbell, Philip
    Prosser, Ian
    Underhill, Craig
    Cunningham, Ilona
    Mills, Anthony K.
    Szer, Jeffrey
    Presgrave, Peter
    Filshie, Robin
    BLOOD, 2009, 114 (22) : 695 - 695
  • [27] 5-azacitidine treatment for imminent relapse in patients with high-risk myelodysplastic syndromes or acute myeloid leukaemia after allogeneic peripheral blood stem cell transplantation
    Platzbecker, U.
    Radke, J.
    Kiani, A.
    von Bonin, M.
    Mohr, B.
    Oelschlaegel, U.
    Ehninger, G.
    Bornhaeuser, M.
    Thiede, C.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S81 - S81
  • [28] 5-AZACITIDINE TREATMENT RESTORES RESPONSE TO EPOETIN THERAPY IN HIGH RISK MYELODYSPLASTIC (MDS) PATIENTS
    Volpe, M.
    Volpe, A.
    HAEMATOLOGICA, 2012, 97 : 588 - 589
  • [29] Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine
    Kuendgen, Andrea
    Mueller-Thomas, Catharina
    Urbaniak, Petra
    Lauseker, Michael
    Haferlach, Torsten
    Alpermann, Tamara
    Albuquerque, Andreia
    Kohlmann, Alexander
    Schnittger, Susanne
    Hildebrandt, Barbara
    Royer-Pokora, Brigitte
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    Goetze, Katharina
    BLOOD, 2013, 122 (21)
  • [30] FLOW CYTOMETRY PREDICTS TREATMENT OUTCOME IN INTERMEDIATE-2 AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS TREATED WITH 5-AZACITIDINE
    Alhan, C.
    Westers, T.
    Cali, C.
    Eeltink, C.
    Ossenkoppele, G.
    van de Loosdrecht, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 379 - 380
12345